Exceptional Response of Nelson’s Syndrome to Pasireotide LAR in the Long-Term Follow-up of 9 Years

^* shared last authorship.

Publikationsverlauf

Eingereicht: 18. Februar 2020
Eingereicht: 30. März 2020

Angenommen: 07. April 2020

Artikel online veröffentlicht:
12. November 2020

• References

• 1 Nelson DH, Meakin JW, Dealy JB. et al. ACTH-producing tumor of the pituitary gland. N Engl J Med 1958; 259: 161-164
• 2 Patel J, Eloy JA, Liu JK. Nelson’s syndrome: A review of the clinical manifestations, pathophysiology, and treatment strategies. Neurosurg Focus 2015; 38: E14
• 3 Kurowska M, Nowakowski A, Zieliński G. et al. Temozolomide-induced shrinkage of invasive pituitary adenoma in patient with Nelson’s Syndrome: A case report and review of the literature. Case Rep Endocrinol 2015; 2015: 623092
• 4 Feelders RA, de Herder WW, Neggers SJ. et al. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors. Drugs Today (Barc) 2013; 49: 89-103
• 5 de Bruin C, Pereira AM, Feelders RA. et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab 2009; 94: 1118-1124
• 6 Lau D, Rutledge C, Aghi MK. Cushing’s disease: Current medical therapies and molecular insights guiding future therapies. Neurosurg Focus 2015; 38: E11
• 7 Katznelson L. Sustained improvements in plasma ACTH and clinical status in a patient with Nelson’s syndrome treated with pasireotide LAR, a multireceptor somatostatin analog. J Clin Endocrinol Metab 2013; 98: 1803-1807
• 8 Daniel E, Debono M, Caunt S. et al. A prospective longitudinal study of Pasireotide in Nelson’s syndrome. Pituitary 2018; 21: 247-255